

Evaluated study abstracts [1-136]

- 1 Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. *Am J Ophthalmol* 2010;150:315-24 e1.doi:10.1016/j.ajo.2010.04.011.
- 2 Adjunctive Diclofenac with Verteporfin Study G, Boyer DS, Beer PM, et al. Effect of adjunctive diclofenac with verteporfin therapy to treat choroidal neovascularization due to age-related macular degeneration: phase II study. *Retina* 2007;27:693-700.doi:10.1097/IAE.0b013e318030e519.
- 3 Agurto-Rivera R, Diaz-Rubio J, Torres-Bernal L, et al. Intravitreal triamcinolone with transpupillary therapy for subfoveal choroidal neovascularization in age related macular degeneration. A randomized controlled pilot study [ISRCTN74123635]. *BMC Ophthalmol* 2005;5:27.doi:10.1186/1471-2415-5-27.
- 4 Ahmadi A, Ghanbari H, Soheilian M, et al. The EFFect of HESA-A (natural drug) on visual acuity in age related macular degeneration: a randomized double blind controlled clinical trial. *Afr J Tradit Complement Altern Med* 2009;6:549-53
- 5 Ahmadi H, Taei R, Riaz-Esfahani M, et al. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial. *Retina* 2011;31:1819-26.doi:10.1097/IAE.0b013e31820d58f2.
- 6 Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. *Am J Ophthalmol* 2008;145:862-74.doi:10.1016/j.ajo.2007.12.029.
- 7 Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. *Ophthalmology* 2006;113:2243-50.doi:10.1016/j.opht.2006.04.039.
- 8 Arnold C, Jentsch S, Dawczynski J, et al. Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study. *Nutrition* 2013;29:1412-7.doi:10.1016/j.nut.2013.05.012.
- 9 Arnold C, Winter L, Frohlich K, et al. Macular xanthophylls and omega-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. *JAMA Ophthalmol* 2013;131:564-72.doi:10.1001/jamaophthalmol.2013.2851.
- 10 Augustin AJ, D'Amico DJ, Mieler WF, et al. Safety of posterior juxtascleral depot administration of the angiostatic cortisone anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2005;243:9-12.doi:10.1007/s00417-004-0961-4.
- 11 Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. *Arch Ophthalmol* 2005;123:448-57.doi:10.1001/archopht.123.4.448.
- 12 Barakat MR, Metelitsina TI, DuPont JC, et al. Effect of niacin on retinal vascular diameter in patients with age-related macular degeneration. *Curr Eye Res* 2006;31:629-34.doi:10.1080/02713680600760501.
- 13 Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. *Arch Ophthalmol* 2007;125:1357-61.doi:10.1001/archopht.125.10.1357.
- 14 Beatty S, Chakravarthy U, Nolan JM, et al. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. *Ophthalmology* 2013;120:600-6.doi:10.1016/j.opht.2012.08.040.
- 15 Berrow EJ, Bartlett HE, Eperjesi F, et al. The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy -- a randomised controlled trial. *Br J Nutr* 2013;109:2008-14.doi:10.1017/S0007114512004187.
- 16 Blaha M, Rencova E, Blaha V, et al. The importance of rheological parameters in the therapy of microcirculatory disorders. *Clin Hemorheol Microcirc* 2009;42:37-46.doi:10.3233/CH-2009-1184.

- 17 Blaha M, Rencova E, Langrova H, et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. *Atheroscler Suppl* 2013;14:179-84.doi:10.1016/j.atherosclerosissup.2012.10.023.
- 18 Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. *Ophthalmology* 2009;116:1731-9.doi:10.1016/j.ophtha.2009.05.024.
- 19 Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. *Ophthalmology* 2004;111:1993-2006.doi:10.1016/j.ophtha.2004.07.023.
- 20 Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. *Ophthalmology* 2013;120:349-54.doi:10.1016/j.ophtha.2012.08.008.
- 21 Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. *Ophthalmology* 2011;118:1089-97.doi:10.1016/j.ophtha.2011.02.039.
- 22 Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1432-44.doi:10.1056/NEJMoa062655.
- 23 Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. *Ophthalmology* 2009;116:57-65 e5.doi:10.1016/j.ophtha.2008.10.018.
- 24 Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. *Ophthalmology* 2013;120:1046-56.doi:10.1016/j.ophtha.2012.10.014.
- 25 Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. *Lancet* 2013;382:1258-67.doi:10.1016/S0140-6736(13)61501-9.
- 26 Chang MA, Do DV, Bressler SB, et al. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. *Retina* 2010;30:1171-6.doi:10.1097/IAE.0b013e3181dd6d8a.
- 27 Chaudhary V, Mao A, Hooper PL, et al. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. *Ophthalmology* 2007;114:2183-9.doi:10.1016/j.ophtha.2007.02.013.
- 28 Cohen SY, Bourgeois H, Corbe C, et al. Randomized clinical trial France DMLA2: effect of trimetazidine on exudative and nonexudative age-related macular degeneration. *Retina* 2012;32:834-43.doi:10.1097/IAE.0b013e31822058a3.
- 29 Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-98.doi:10.1016/j.ophtha.2012.03.053.
- 30 Costagliola C, Romano MR, Rinaldi M, et al. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. *Br J Ophthalmol* 2010;94:180-4.doi:10.1136/bjo.2009.159343.
- 31 Danis R, McLaughlin MM, Tolentino M, et al. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. *Br J Ophthalmol* 2014;98:172-8.doi:10.1136/bjophthalmol-2013-303117.
- 32 Dawczynski J, Jentsch S, Schweitzer D, et al. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. *Graefes Arch Clin Exp Ophthalmol* 2013;251:2711-23.doi:10.1007/s00417-013-2376-6.
- 33 Dugel PU, Bebbchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). *Ophthalmology* 2013;120:317-27.doi:10.1016/j.ophtha.2012.07.068.

- 34 Dunavoelgyi R, Sacu S, Simader C, et al. Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. *Acta Ophthalmol* 2011;89:166-71.doi:10.1111/j.1755-3768.2009.01646.x.
- 35 Eklund K, Sjostrand J, Dahlin-Ivanoff S. A randomized controlled trial of a health-promotion programme and its effect on ADL dependence and self-reported health problems for the elderly visually impaired. *Scand J Occup Ther* 2008;15:68-74.doi:10.1080/11038120701442963.
- 36 El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. *Am J Ophthalmol* 2012;153:481-9 e1.doi:10.1016/j.ajo.2011.08.018.
- 37 Falkner-Radler CI, Krebs I, Glittenberg C, et al. Human retinal pigment epithelium (RPE) transplantation: outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. *Br J Ophthalmol* 2011;95:370-5.doi:10.1136/bjo.2009.176305.
- 38 Falsini B, Piccardi M, Minnella A, et al. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2010;51:6118-24.doi:10.1167/iovs.09-4995.
- 39 Feher J, Kovacs B, Kovacs I, et al. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. *Ophthalmologica* 2005;219:154-66.doi:10.1159/000085248.
- 40 Figueroa M, Schocket LS, DuPont J, et al. Long-term effect of laser treatment for dry age-related macular degeneration on choroidal hemodynamics. *Am J Ophthalmol* 2006;141:863-7.doi:10.1016/j.ajo.2005.11.049.
- 41 Flaxel C, Schain MB, Hamon SC, et al. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. *Retina* 2012;32:417-23.doi:10.1097/IAE.0b013e318229b0af.
- 42 Frennesson CI, Bek T, Jaakkola A, et al. Prophylactic laser treatment of soft drusen maculopathy: a prospective, randomized Nordic study. *Acta Ophthalmol* 2009;87:720-4.doi:10.1111/j.1755-3768.2008.01396.x.
- 43 Friberg TR, Musch DC, Lim JI, et al. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. *Ophthalmology* 2006;113:622 e1.doi:10.1016/j.ophtha.2005.10.066.
- 44 Fung AT, Kumar N, Vance SK, et al. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). *Eye (Lond)* 2012;26:1181-7.doi:10.1038/eye.2012.174.
- 45 Garcia-Layana A, Recalde S, Alaman AS, et al. Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial. *Nutrients* 2013;5:543-51.doi:10.3390/nu5020543.
- 46 Gelisken F, Voelker M, Schwabe R, et al. Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). *Graefes Arch Clin Exp Ophthalmol* 2007;245:1085-95.doi:10.1007/s00417-006-0524-y.
- 47 Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. *Arch Ophthalmol* 2004;122:336-40.doi:10.1001/archophth.122.3.336.
- 48 Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004;351:2805-16.doi:10.1056/NEJMoa042760.
- 49 Group AHSR, Chew EY, Clemons TE, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. *Ophthalmology* 2014;121:535-44.doi:10.1016/j.ophtha.2013.10.027.
- 50 Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med* 2011;364:1897-908.doi:10.1056/NEJMoa1102673.

- 51 Group VISIONCT, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:1508 e1-25.doi:10.1016/j.ophtha.2006.02.064.
- 52 Group VISIONCT, D'Amico DJ, Masonson HN, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. *Ophthalmology* 2006;113:992-1001 e6.doi:10.1016/j.ophtha.2006.02.027.
- 53 Gustavsson C, Agardh E. Transpupillary thermotherapy for occult subfoveal choroidal neovascularization: a 1-year, prospective randomized pilot study. *Acta Ophthalmol Scand* 2005;83:148-53.doi:10.1111/j.1600-0420.2005.00427.x.
- 54 Guymer RH, Baird PN, Varsamidis M, et al. Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS One* 2013;8:e83759.doi:10.1371/journal.pone.0083759.
- 55 Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. *Ophthalmology* 2004;111:1967-80.doi:10.1016/j.ophtha.2004.07.021.
- 56 Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. *Ophthalmology* 2006;113:633 e1-4.doi:10.1016/j.ophtha.2005.10.052.
- 57 Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. *Ophthalmology* 2011;118:1098-106.doi:10.1016/j.ophtha.2011.03.020.
- 58 Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. *Arch Ophthalmol* 2006;124:1532-42.doi:10.1001/archophth.124.11.1532.
- 59 Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology* 2012;119:2537-48.doi:10.1016/j.ophtha.2012.09.006.
- 60 Huang YM, Yan SF, Ma L, et al. Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. *Nutrition* 2013;29:387-92.doi:10.1016/j.nut.2012.06.009.
- 61 Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. *Ophthalmology* 2012;119:1399-411.doi:10.1016/j.ophtha.2012.04.015.
- 62 Jaakkola A, Heikkinen J, Tommila P, et al. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. *Ophthalmology* 2005;112:567-73.doi:10.1016/j.ophtha.2004.11.029.
- 63 Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. *Ophthalmology* 2013;120:1893-900.doi:10.1016/j.ophtha.2013.02.016.
- 64 Jackson TL, Dugel PU, Bechuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography. *Ophthalmology* 2013;120:1597-603.doi:10.1016/j.ophtha.2013.01.074.
- 65 Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. *Ophthalmology* 2012;119:1001-10.doi:10.1016/j.ophtha.2012.02.003.
- 66 Kaiser PK, Visudyne In Occult CNVsg. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. *Curr Med Res Opin* 2009;25:1853-60.doi:10.1185/03007990903038616.
- 67 Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. *Ophthalmology* 2013;120:2300-9.doi:10.1016/j.ophtha.2013.06.020.
- 68 Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. *Br J Ophthalmol* 2013;97:266-71.doi:10.1136/bjophthalmol-2012-302391.

- 69 Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. *Acta Ophthalmol* 2013;91:e178-83.doi:10.1111/aos.12018.
- 70 Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. *Ophthalmology* 2012;119:992-1000.doi:10.1016/j.ophtha.2012.02.002.
- 71 Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. *Ophthalmology* 2007;114:1179-85.doi:10.1016/j.ophtha.2007.03.006.
- 72 Lee J, Freeman WR, Azen SP, et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. *Retina* 2007;27:1205-13.doi:10.1097/IAE.0b013e31815ec367.
- 73 Li X, Hu Y, Sun X, et al. Bevacizumab for neovascular age-related macular degeneration in China. *Ophthalmology* 2012;119:2087-93.doi:10.1016/j.ophtha.2012.05.016.
- 74 Lushchik T, Amarakoon S, Martinez-Ciriano JP, et al. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks. *Acta Ophthalmol* 2013;91:e456-61.doi:10.1111/aos.12119.
- 75 Ma L, Dou HL, Huang YM, et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. *Am J Ophthalmol* 2012;154:625-34 e1.doi:10.1016/j.ajo.2012.04.014.
- 76 Ma L, Yan SF, Huang YM, et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. *Ophthalmology* 2012;119:2290-7.doi:10.1016/j.ophtha.2012.06.014.
- 77 Maberley D, Canadian Retinal Trials G. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. *Ophthalmology* 2009;116:2149-57 e1.doi:10.1016/j.ophtha.2009.04.032.
- 78 Marcus DM, Peskin E, Maguire M, et al. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. *Am J Ophthalmol* 2004;138:818-28.doi:10.1016/j.ajo.2004.06.081.
- 79 Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. *Retina* 2013;33:498-507.doi:10.1097/IAE.0b013e318265801d.
- 80 Menon G, Chandran M, Sivaprasad S, et al. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). *Eye (Lond)* 2013;27:959-63.doi:10.1038/eye.2013.93.
- 81 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of niacin on the choroidal circulation of patients with age related macular degeneration. *Br J Ophthalmol* 2004;88:1568-72.doi:10.1136/bjo.2004.046607.
- 82 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of Viagra on the foveolar choroidal circulation of AMD patients. *Exp Eye Res* 2005;81:159-64.doi:10.1016/j.exer.2005.01.017.
- 83 Metelitsina TI, Grunwald JE, DuPont JC, et al. Effect of viagra on retinal vein diameter in AMD patients. *Exp Eye Res* 2006;83:128-32.doi:10.1016/j.exer.2005.11.012.
- 84 Michels S, Wachtlin J, Gamulescu MA, et al. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. *Ophthalmology* 2005;112:2070-5.doi:10.1016/j.ophtha.2005.06.034.
- 85 Modarres M, Naseripour M, Falavarjani KG, et al. Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. *Retina* 2009;29:319-24.doi:10.1097/IAE.0b013e318198148e.
- 86 Murray IJ, Makridaki M, van der Veen RL, et al. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. *Invest Ophthalmol Vis Sci* 2013;54:1781-8.doi:10.1167/iovs.12-10715.

- 87 Myint K, Armbrecht AM, Mon S, et al. Transpupillary thermotherapy for the treatment of occult CNV in age-related macular degeneration: a prospective randomized controlled pilot study. *Acta Ophthalmol Scand* 2006;84:328-32.doi:10.1111/j.1600-0420.2005.00623.x.
- 88 Neovascular Age-Related Macular Degeneration PC, Photodynamic Therapy Trial Research G, Gilson MM, et al. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. *Ophthalmology* 2007;114:1713-21.doi:10.1016/j.ophtha.2007.03.071.
- 89 Nguyen QD, Campochiaro PA, Shah SM, et al. Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. *J Ocul Pharmacol Ther* 2012;28:581-8.doi:10.1089/jop.2011.0261.
- 90 Nguyen QD, Schachar RA, Nduaka CI, et al. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). *Ophthalmology* 2012;119:1867-73.doi:10.1016/j.ophtha.2012.03.043.
- 91 Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. *Ophthalmology* 2006;113:1522 e1- e14.doi:10.1016/j.ophtha.2006.05.055.
- 92 Nussenblatt RB, Byrnes G, Sen HN, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. *Retina* 2010;30:1579-87.doi:10.1097/IAE.0b013e3181e7978e.
- 93 Odergren A, Algvere PV, Seregard S, et al. A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. *Br J Ophthalmol* 2008;92:757-61.doi:10.1136/bjo.2007.133561.
- 94 Parodi MB, Toto L, Mastropasqua L, et al. Prismatic correction in patients affected by age-related macular degeneration. *Clin Rehabil* 2004;18:828-32.doi:10.1191/0269215504cr801oa.
- 95 Piermarocchi S, Sartore M, Lo Giudice G, et al. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. *Arch Ophthalmol* 2008;126:1367-74.doi:10.1001/archophth.126.10.1367.
- 96 Piermarocchi S, Saviano S, Parisi V, et al. Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study. *Eur J Ophthalmol* 2012;22:216-25.doi:10.5301/ejo.5000069.
- 97 Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. *Br J Ophthalmol* 2010;94:174-9.doi:10.1136/bjo.2008.155531.
- 98 Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. *Trans Am Ophthalmol Soc* 2006;104:221-31
- 99 Ranchod TM, Ray SK, Daniels SA, et al. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. *Retina* 2013;33:1600-4.doi:10.1097/IAE.0b013e318285cb71.
- 100 Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. *Am J Ophthalmol* 2008;145:239-48.doi:10.1016/j.ajo.2007.10.004.
- 101 Rencova E, Blaha M, Studnicka J, et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. *Acta Ophthalmol* 2011;89:463-71.doi:10.1111/j.1755-3768.2009.01710.x.
- 102 Richer S, Devenport J, Lang JC. LAST II: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. *Optometry* 2007;78:213-9.doi:10.1016/j.optm.2006.10.019.
- 103 Richer S, Stiles W, Statkute L, et al. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). *Optometry* 2004;75:216-30

- 104 Richer SP, Stiles W, Graham-Hoffman K, et al. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. *Optometry* 2011;82:667-80 e6.doi:10.1016/j.optm.2011.08.008.
- 105 Rosenfeld PJ, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study. *Am J Ophthalmol* 2007;144:970-2.doi:10.1016/j.ajo.2007.08.017.
- 106 Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1419-31.doi:10.1056/NEJMoa054481.
- 107 Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:623 e1.doi:10.1016/j.ophtha.2006.01.027.
- 108 Rosenthal JM, Kim J, de Monasterio F, et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. *Invest Ophthalmol Vis Sci* 2006;47:5227-33.doi:10.1167/iovs.05-1513.
- 109 Russo A, Costagliola C, Delcassi L, et al. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. *Br J Ophthalmol* 2013;97:1273-6.doi:10.1136/bjophthalmol-2013-303417.
- 110 Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. *Eye (Lond)* 2009;23:2223-7.doi:10.1038/eye.2008.423.
- 111 Sacu S, Varga A, Michels S, et al. Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study. *Br J Ophthalmol* 2008;92:1347-51.doi:10.1136/bjo.2008.137885.
- 112 Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. *Retina* 2010;30:1390-9.doi:10.1097/IAE.0b013e3181e44599.
- 113 Sarraf D, Chan C, Rahimy E, et al. Prospective evaluation of the incidence and risk factors for the development of RPE tears after high- and low-dose ranibizumab therapy. *Retina* 2013;33:1551-7.doi:10.1097/IAE.0b013e31828992f5.
- 114 Schmid-Kubista KE, Krebs I, Ansari-Shahrezaei S, et al. Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy--a pilot study. *Curr Eye Res* 2011;36:958-63.doi:10.3109/02713683.2011.597536.
- 115 Schmid-Kubista KE, Krebs I, Gruenberger B, et al. Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. *Br J Ophthalmol* 2009;93:914-9.doi:10.1136/bjo.2008.144410.
- 116 Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. *Ophthalmology* 2011;118:831-9.doi:10.1016/j.ophtha.2010.09.004.
- 117 Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. *Ophthalmology* 2014;121:193-201.doi:10.1016/j.ophtha.2013.08.011.
- 118 Schmidt-Erfurth U, Sacu S, Early Retreatment Study G. Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. *Ophthalmology* 2008;115:134-40.doi:10.1016/j.ophtha.2007.02.033.
- 119 Schmidt-Erfurth UM, Elsner H, Terai N, et al. Effects of verteporfin therapy on central visual field function. *Ophthalmology* 2004;111:931-9.doi:10.1016/j.ophtha.2003.12.025.
- 120 Sin M, Chrapek O, Karhanova M, et al. Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014;158:138-43.doi:10.5507/bp.2012.066.
- 121 Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. *Br J Ophthalmol* 2008;92:1606-11.doi:10.1136/bjo.2007.132597.

- 122 Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. *Ophthalmology* 2006;113:3-13.doi:10.1016/j.ophtha.2005.10.019.
- 123 Soderberg AC, Algvere PV, Hengstler JC, et al. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study. *Br J Ophthalmol* 2012;96:714-8.doi:10.1136/bjophthalmol-2011-300721.
- 124 Souayah N, Khella SL. A prospective double-blind, placebo-controlled study of thalidomide sensory symptoms in an elderly population with age-related macular degeneration. *J Clin Neurosci* 2010;17:571-3.doi:10.1016/j.jocn.2009.09.017.
- 125 Souied EH, Delcourt C, Querques G, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study. *Ophthalmology* 2013;120:1619-31.doi:10.1016/j.ophtha.2013.01.005.
- 126 Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. *Eye (Lond)* 2010;24:1708-15.doi:10.1038/eye.2010.147.
- 127 Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. *Am J Ophthalmol* 2009;148:875-82 e1.doi:10.1016/j.ajo.2009.07.009.
- 128 Sun YD, Dong YD, Fan R, et al. Effect of (R)-alpha-lipoic acid supplementation on serum lipids and antioxidative ability in patients with age-related macular degeneration. *Ann Nutr Metab* 2012;60:293-7.doi:10.1159/000338444.
- 129 Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. *BMJ* 2010;340:c2459.doi:10.1136/bmj.c2459.
- 130 Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. *Eye (Lond)* 2010;24:1561-7.doi:10.1038/eye.2010.84.
- 131 Weigert G, Kaya S, Pemp B, et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. *Invest Ophthalmol Vis Sci* 2011;52:8174-8.doi:10.1167/iovs.11-7522.
- 132 Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. *Br J Ophthalmol* 2008;92:356-60.doi:10.1136/bjo.2007.125823.
- 133 Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. *Ophthalmology* 2014;121:693-701.doi:10.1016/j.ophtha.2013.09.044.
- 134 Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. *Ophthalmology* 2006;113:2012-9.doi:10.1016/j.ophtha.2006.05.036.
- 135 Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. *Proc Natl Acad Sci U S A* 2011;108:6241-5.doi:10.1073/pnas.1018987108.
- 136 Ziemssen F, Luke M, Bartz-Schmidt KU, et al. Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). *Graefes Arch Clin Exp Ophthalmol* 2008;246:653-9.doi:10.1007/s00417-007-0726-y.